ProQR Announces Results for the Second Quarter of 2015 Press release … of severe diseases such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA), today announced results for the second … August 19, 2015
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Press release … in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) Presenter: Stephen R. Russell, MD, … April 23, 2021
ProQR Therapeutics Announces Results for the Fourth Quarter and Full Year 2014 Press release … treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, today announced results for the fourth quarter and … February 26, 2015
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Press release … 2/3 Illuminate study of sepofarsen for the treatment of Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation in the … January 07, 2021
ProQR to Present at the JMP Securities Life Science Conference Press release … treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, today announced that Daniel de Boer, Chief … June 16, 2015
ProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable Press release … treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis, today announced that Daniel de Boer, Chief … September 23, 2015
ProQR Announces Second Quarter 2020 Operating and Financial Results Press release … Program Updates Ongoing clinical studies of sepofarsen for Leber Congenital Amaurosis 10 (LCA10), QR-421a for Usher syndrome and … August 06, 2020
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021 Press release … will be available for viewing until July 15, 2021. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital amaurosis (LCA) is the … April 02, 2021
ProQR Announces Virtual Presentations at Scientific Conferences Press release … trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: Stephen R. Russell, MD, … September 24, 2020
ProQR Announces Highlights from Analyst Event Press release … include the following: Sepofarsen for CEP290 -mediated Leber congenital amaurosis 10 (LCA10): The Company expects to report top-line … November 18, 2021